文献速递头颈部肿瘤放疗

口咽癌剂量递增:同步整合推量与近距离放疗推量的比较

Dose escalation in oropharyngeal cancer: a comparison of simultaneous integrated boost and brachytherapy boost.
PubMed 文献 · Radiat Oncol · 2023-04-07

本研究回顾性分析2011至2018年在本机构因口咽鳞状细胞癌接受>72 Gy治疗的244例连续患者,比较同步整合推量(SIB)与近距离放疗推量两种剂量递增方式的生存和毒性结局。结果显示两种推量方式在总生存、无进展生存及≥3级副作用方面均无显著差异,倾向性评分匹配分析后结果不变。

要点

  • 口咽鳞状细胞癌接受SIB推量111例,近距离放疗推量134例,两组生存无显著差异。
  • 两种剂量递增技术的≥3级副作用无显著差异。

核心结论

  • 在口咽癌治疗中,同步整合推量与近距离放疗推量作为替代剂量递增方式,在生存和≥3级副作用方面无显著差异。

研究设计与样本

  • 回顾性分析2011至2018年在本机构接受>72 Gy治疗的244例连续口咽鳞状细胞癌患者,比较SIB推量与近距离放疗推量的治疗和毒性结局。

主要发现

  • SIB推量组111例,近距离放疗推量组134例;最常见肿瘤部位为舌根(55%),其次为扁桃体癌(42%);多数患者为T3或T4期肿瘤,84%为HPV阳性。
  • 两种剂量递增方式在总生存或无进展生存方面无显著差异,倾向性评分匹配分析后结果不变。
  • 两种剂量递增技术的≥3级副作用分析显示无显著差异。

关键数值与推荐

  • 近距离放疗推量组先接受外照射放疗:大体肿瘤体积(GTV)68 Gy分2 Gy/次,双侧颈部选择性放疗;近距离放疗推量通常采用脉冲剂量率,15次,每次0.56-0.66 Gy[EQD2总量=75.4-76.8 Gy(α/β=10)]。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Local recurrence is the most common pattern of failure in head and neck cancer. It can therefore be hypothesised that some of these patients would benefit from an intensified local treatment, such as radiation dose escalation of the primary tumour. This study compares treatment and toxicity outcomes from two different boost modalities in oropharyngeal cancer: simultaneous integrated boost (SIB) and brachytherapy boost. METHODS: Two hundred and forty-four consecutive patients treated with > 72 Gy for oropharyngeal squamous cell carcinoma between 2011 and 2018 at our institution were retrospectively analysed. Data on side effects were collected from a local quality registry and supplemented with a review of medical records. Patients receiving a brachytherapy boost first had external beam radiotherapy consisting of 68 Gy in 2 Gy fractions to the gross tumour volume (GTV), and elective radiotherapy to the neck bilaterally. The brachytherapy boost was typically given using pulsed dose rate, 15 fractions and 0.56-0.66 Gy per fraction [total dose in EQD2 = 75.4-76.8 Gy (α/β = 10)]. The typical dose escalated radiotherapy with external beam radiotherapy only, was delivered using SIB with 74,8 Gy in 2.2 Gy fractions [EQD2 = 76.0 Gy (α/β = 10)] to the primary tumour, 68 Gy in 2 Gy fractions to GTV + 10 mm margin and elective radiotherapy to the neck bilaterally. RESULTS: Dose escalation by SIB was given to 111 patients and brachytherapy boost to 134 patients. The most common type of cancer was base of tongue (55%), followed by tonsillar cancer (42%). The majority of patients had T3- or T4-tumours and 84% were HPV-positive. The 5-year OS was 72,4% (95% CI 66.9-78.3) and the median follow-up was 6.1 years. Comparing the two different dose escalation modalities we found no significant differences in OS or PFS and these results remained after a propensity-score matched analysis was performed. The analysis of grade ≥ 3 side effects showed no significant differences between the two different dose escalation techniques. CONCLUSIONS: We found no significant differences in survival or grade ≥ 3 side effects comparing simultaneous integrated boost and brachytherapy boost as alternative dose escalation modalities in the treatment of oropharyngeal cancer.

来源:Radiat Oncol,查看原文。版权归原作者所有。

引用

  1. Embring A, Onjukka E, Mercke C, et al. Dose escalation in oropharyngeal cancer: a comparison of simultaneous integrated boost and brachytherapy boost. Radiat Oncol. 2023. PMID: 37029424. doi:10.1186/s13014-023-02256-x

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。